In fact, pertuzumab was suggested for the treatment of triple-negative human breast cancer, which express the circular HER2 RNA, encoding for HER2-103, as putatively occurring with the FMCp cell line [51], which is antagonized by pertuzumab [76]. This evidence concerns the gene ERBB2 and breast carcinoma.